Yinghua Xu

1 clinical trials · Sponsor

Record	Firm	Date
A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection (NCT07495215)	Yinghua Xu	2025-09-11

Every clearance here is in the API, with alerts when new ones post.